KU-55933: Potent and Selective ATM Kinase Inhibitor for DNA Damage Response Research

Executive Summary: KU-55933 is a potent ATM kinase inhibitor with an IC₅₀ of 13 nM, conferring high selectivity over related kinases (ApexBio). It effectively inhibits ATM-mediated phosphorylation of Akt at Ser473, reducing cell proliferation and inducing G1 cell cycle arrest in cancer cell lines (Sequiera et al., 2022). KU-55933 modulates cellular metabolism, increasing lactate production and glucose consumption while decreasing ATP in MCF-7 cells. Its performance supports applications in DNA damage response, cell cycle regulation, and disease modeling using iPSC platforms. The compound is stable under recommended storage and preparation conditions, enabling reliable workflow integration.

Biological Rationale

The ataxia-telangiectasia mutated (ATM) kinase is a serine/threonine protein kinase central to the DNA damage response (DDR) pathway. ATM is activated by DNA double-strand breaks and orchestrates cellular responses by phosphorylating key proteins, including p53, Chk2, and Akt at Ser473, which regulate cell cycle checkpoints and survival. Dysregulation of ATM signaling has been implicated in cancer, ataxia-telangiectasia, and other genomic instability syndromes (Sequiera et al., 2022). Targeting ATM with selective inhibitors like KU-55933 enables researchers to dissect the role of ATM in DDR and explore therapeutic strategies for cancer and rare diseases.

Mechanism of Action of KU-55933 (ATM Kinase Inhibitor)

KU-55933 is a small-molecule inhibitor that binds the ATP-binding site of ATM kinase. It exhibits an IC₅₀ of 13 nM and a K_i of 2.2 nM for ATM, demonstrating over 100-fold selectivity compared to related kinases such as DNA-PK, PI3K, PI4K, ATR, and mTOR (ApexBio). By inhibiting ATM, KU-55933 blocks phosphorylation of downstream substrates, notably Akt at Ser473, a modification critical for promoting cell survival and proliferation. This inhibition reduces cyclin D1 expression, driving G1 cell cycle arrest and suppression of tumor cell growth. Additionally, KU-55933 impacts cellular metabolism by enhancing glycolytic flux (as evidenced by increased lactate and glucose uptake) and decreasing ATP levels in certain cancer cell lines.

Evidence & Benchmarks

• KU-55933 demonstrates an IC₅₀ of 13 nM and a K_i of 2.2 nM for ATM kinase under standard in vitro assay conditions (ApexBio).
• At 10 μM, KU-55933 inhibits proliferation by approximately 50% in MDA-MB-453 and PC-3 cancer cell lines (standard cell culture, 24–48h exposure) (ApexBio).
• ATM selectivity: KU-55933 shows over 100-fold selectivity for ATM versus DNA-PK, PI3K/PI4K, ATR, and mTOR, as determined by kinase profiling (ApexBio).
• Induces G1 cell cycle arrest via cyclin D1 downregulation in cancer models (Sequiera et al., 2022).
• In MCF-7 cells, KU-55933 increases lactate production and glucose consumption, and lowers ATP levels after 24h treatment (metabolic flux analysis) (Sequiera et al., 2022).
• Compatible with iPSC-based disease modeling platforms for assessing DNA damage responses and drug efficacy (Sequiera et al., 2022).

Applications, Limits & Misconceptions

KU-55933 has been widely adopted in research focused on DDR, cell cycle regulation, apoptosis, and cancer biology. Its high selectivity enables precise interrogation of ATM-specific signaling events, minimizing off-target effects. KU-55933 is also used in iPSC-based disease models to assess individual drug responses, especially in ultrarare disease contexts where ATM pathway aberrations are implicated (Sequiera et al., 2022).

This article extends previous site coverage by providing up-to-date quantitative performance metrics and iPSC-based applications, going beyond the scope of this overview of ATM inhibition in iPSC models and clarifying recent advances in metabolic modulation described in this article on translational workflows.

Common Pitfalls or Misconceptions

• Not a pan-PI3K inhibitor: KU-55933 is highly selective for ATM and does not significantly inhibit PI3K, mTOR, or DNA-PK at working concentrations (ApexBio).
• Water/Ethanol Insolubility: The compound is insoluble in water and ethanol, requiring DMSO (≥41.67 mg/mL with gentle warming) for stock preparation (ApexBio).
• Not suitable for in vivo use: KU-55933 is primarily validated for cell-based and in vitro assays; in vivo pharmacokinetics, bioavailability, and systemic toxicity remain uncharacterized (Sequiera et al., 2022).
• Short-term stock stability: Working solutions should be used promptly; only solid or frozen stocks are stable for months (ApexBio).
• ATM-independent DDR pathways: Some DNA damage responses are ATM-independent; KU-55933 will not inhibit such signaling events (Related Article).

Workflow Integration & Parameters

• Storage: Store solid KU-55933 desiccated at -20°C. Stock solutions in DMSO are stable below -20°C for several months. Avoid long-term storage at room temperature or in aqueous media.
• Solubility: Dissolve in DMSO at ≥41.67 mg/mL with gentle warming. Compound is insoluble in water and ethanol.
• Assay Preparation: Dilute working solutions into assay buffer or cell culture media immediately prior to use, keeping final DMSO concentration ≤0.1% v/v to avoid cytotoxicity.
• Recommended Concentrations: Effective in vitro concentrations range from 0.1 μM to 10 μM, depending on assay; benchmark proliferation inhibition at 10 μM.
• Use in iPSC Models: Integrate with iPSC-derived cell lines for personalized drug response phenotyping, as shown in ultrarare disease platforms (Sequiera et al., 2022).

For comprehensive workflows and advanced integration, see the dedicated KU-55933 (ATM Kinase Inhibitor) product dossier and our detailed analysis of ATM signaling crosstalk in this article, which complements the present review by focusing on cGAS regulation and genome integrity.

Conclusion & Outlook

KU-55933 is a gold-standard ATM kinase inhibitor that has transformed research into DNA damage checkpoint signaling, cell cycle arrest, and cancer metabolism. Its selectivity and performance in cellular and iPSC-based models make it indispensable for dissecting ATM functions and evaluating candidate therapeutics for cancer and rare genetic disorders. Future progress will hinge on expanding its translational use in personalized medicine, especially when integrated with preclinical iPSC platforms (Sequiera et al., 2022). For more information, consult the full A4605 kit details and the latest translational updates.